Firm is "in discussions with a number of major health care companies" for outlicensing genetically engineered fibroblast growth factors (FGF), currently in preclinicals for wound healing. Cal Bio told analysts Sept. 14 that it has cloned and expressed genes for both basic and acidic FGF and is "concentrating on the use of the more powerful basic FGF for a variety of wound-healing uses".
You may also be interested in...
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.